Study design, patient selection, and randomization
EVENTS
The study design was an a prospective, open-label, randomized, non-blinded, non-inferiority pilot study in which 36 consecutive adult patients undergoing living-donor kidney transplantation were randomly assigned to receive either 4.5 mg/kg (n = 19) or 6.0 mg/kg (n = 17) of ATG at Asan Medical Center (Seoul, South Korea); the enrollment of patients was initiated in January 2016. The data safety monitoring board at our center ceased the trial in September 2017, which was due to the more frequently observed composite events of biopsy-proven acute rejection (BPAR) and All patients were randomly assigned in a computer-generated 1:1 variable-block randomization performed by a study coordinator at our center to receive ATG (Thymoglobuline